PharmaMar presents in oral session at ASCO the ADMYRE study’s adjusted overall survival with plitidepsin
The modelled data on overall survival of the statistical evaluation of the impact of crossover on the ADMYRE study were presented. Of the 84 patients treated in the comparator arm (dexamethasone as a single agent), 44% received the combination with plitidepsin after progression. After analyzing the impact of crossover, the registered overall survival with plitidepsin was 11.6 months against the 6.4 months of dexamethasone alone.
Madrid, 5th June, 2018. – PharmaMar (MSE:PHM) has presented today how crossover has had an influence on the overall survival of the ADMYRE trial. The impact on overall survival of those patients that relapsed after receiving dexamethasone as a single agent and who were subsequently treated with plitidepsin in combination with dexamethasone was analyzed. Of the 84 patients treated from the comparator arm -dexamethasone as a single agent- 44%, 37 patients were treated with the combination with plitidepsin thereafter.
This data has been presented as a poster discussion session during the American Society of Clinical Oncology (ASCO) that is being held from the 1st to the 5th of June in Chicago (USA).
The ADMYRE study is a
Article originally posted at